Abeona Therapeutics Q3 profit beats analyst expectations

Abeona Therapeutics

12/11/2025 12:40

Overview

Abeona Q3 net income and EPS beat analyst expectations

Company's cash position at $207.5 mln, sufficient for over two years of operations

Outlook

Company anticipates ZEVASKYN patient treatments to start in 4Q 2025

Abeona sees strong patient demand and expanding treatment site network

Result Drivers

PATIENT DEMAND - Abeona reports strong and growing patient demand for ZEVASKYN despite treatment delay

TREATMENT CENTER EXPANSION - Strategic expansion of QTC network with three activated centers and more onboarding

MARKET ACCESS - Broad market access with commercial payer coverage and CMS J-code for ZEVASKYN

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
Beat
-$0.10
-$0.29 (7 Analysts)
Q3 Net Income
Beat
-$5.16 mln
-$16.90 mln (7 Analysts)
Q3 Income From Operations
Miss
-$24.02 mln
-$18.20 mln (7 Analysts)
Q3 Cash & Investments
$207.50 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Abeona Therapeutics Inc is $20.00, about 79.1% above its November 11 closing price of $4.17

Press Release: ID:nGNX5qyZHr

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)